http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BD Names Dr. Carrie Byington To Board Of Directors
-
BD Launches New 'Together We Advance' Environmental, Social, Governance Strategy; Announces 2030+ Goals to Enhance Stewardship of Human Health, Communities and the Planet
-
BD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Vaccination Agility and Preparedness
-
Becton Dickinson (BDX) Announces 510(k) Clearance of Expanded Indications for Rotarex Atherectomy System
-
BD Announces 510(k) Clearance of Expanded Indications for the Rotarex™ Atherectomy System
-
BD To Announce Fiscal 2021 Fourth Quarter And Full Year Financial Results
-
BD Joins the Race to Zero: Largest Alliance Dedicated to Achieving Net Zero Emissions by 2050
-
BD Partners with Washington State in Back-to-School Testing Effort
-
BD to Present at Two Upcoming Virtual Healthcare Investor Conferences in September
-
Becton Dickinson (BDX) Receives Emergency Use Authorization BD Veritor™ At-Home COVID-19 Test
-
BD Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results
-
Becton Dickinson (BDX) Launches Fully Automated High-Throughput Molecular Diagnostic Platform for U.S. Laboratories
-
BD Launches Fully Automated High-Throughput Molecular Diagnostic Platform for U.S. Laboratories
-
New BD Benchtop Cell Analyzer Enhances Laboratory Access and Accelerates Scientific Research
-
Becton Dickinson (BDX) Appoints Christopher DelOrefice as CFO
-
Christopher DelOrefice to Join BD as Chief Financial Officer
-
BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021
-
Christopher Reidy Announces Intent to Retire from BD
-
BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit
-
BD to Begin Remediation for BD Alaris™ System Software
-
BD Board Declares Dividend
-
Becton Dickinson (BDX) Acquires Tepha
-
BD Acquires Tepha, Inc., to Drive New Innovations in Soft Tissue Repair and Regeneration
-
Becton Dickinson (BDX) Annouonces Acquisition of Velano Vascular
-
BD Seeks to Transform Patient Experience through Vision of 'One-Stick Hospital Stay'
-
Free and Charitable Clinics Receive Grant for Point-of-Care Diagnostics
-
BD Announces Two Future Directors for Diabetes Care Spinoff Company
-
BD Launches Reimagined Digital Marketplace for Flow Cytometry
-
BD To Announce Financial Results For Its Third Quarter Of Fiscal 2021
-
Becton Dickinson (BDX) Granted FDA 510(k) Clearance for At-Home System for Ascites
-
BD Announces Expanded 510(k) Clearance for At-Home System for Ascites
-
BD Highlights Five-Year ESG Achievements in 2020 Sustainability Report, Setting the Foundation for 2030+ Strategy
-
USA Swimming Partners with BD to Provide COVID-19 Screening for the Olympic Trials and Other Competitive Swimming Events
-
BD Hits 2 Billion Injection Device Milestone in Support of Global COVID-19 Vaccination Efforts
-
PAVmed Launches Digital Health Company Veris Health Inc.
-
BD Advances Leadership in Cybersecurity Preparedness, Transparency
-
BD to Present at Upcoming Investor Conferences in June
-
BD Leverages Artificial Intelligence To Transform Microbiology Urine Testing
-
Becton Dickinson (BDX) Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System
-
BD Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System
-
Becton Dickinson (BDX) to Build New EUR165 Million Manufacturing Facility in Zaragoza, Spain
-
BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business
-
BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples
-
Becton Dickinson (BDX) to Spin Off Diabetes Care Business
-
BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance
-
BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets
-
BD to Present at Upcoming Investor Health Care Conferences in May
-
BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula
-
Elizabeth McCombs Appointed Chief Technology Officer at BD
-
BD Board Declares Dividend

